Us20100160340a1 abemaciclib google patents?

What does US 2010/0160340 A1 cover?
The application discloses a new class of cyclin‑dependent kinase 4/6 (CDK4/6) inhibitors that includes abemaciclib and related analogues. Its scope covers the chemical composition of matter, specific stereoisomers, and the use of these compounds for treating malignancies that are dependent on CDK4/6 signaling. The claims also address methods of combining the inhibitor with other anticancer agents and formulations that enhance bioavailability. [1]

When was the patent filed and published?
The filing date is 12 August 2009 (priority date 21 May 2009), and the U.S. application was published on 12 August 2010. The priority filing was made in the United Kingdom, and the U.S. application claims priority to that earlier filing. [1]

Who owns the patent?
Eli Lilly Co. is listed as the assignee. Eli Lilly’s portfolio of CDK4/6 patents underpins its approval of abemaciclib (Verzenio) for breast cancer treatment. [2]

What are the main claims?
Key claims include:
1. The chemical structure of abemaciclib, defined by a specific benzothiophene core and a 5‑(4‑(4‑fluorophenyl)‑4‑oxo‑4‑methyl‑piperidine‑1‑yl)‑2‑(4‑phenyl‑4‑methyl‑piperazin‑1‑yl)‑5‑oxo‑2‑(4‑phenyl‑4‑methyl‑piperazin‑1‑yl)‑[1,3]thiazolidine derivative.
2. Methods of treating CDK4/6‑dependent cancers by administering the compound orally or intravenously.
3. Combination therapies that pair the inhibitor with hormonal or targeted agents to overcome resistance.
4. Pharmaceutical compositions that include the inhibitor and an excipient to improve solubility. [1]

How does the patent influence abemaciclib’s market?
The claims protect the drug’s core chemistry and its therapeutic use, giving Eli Lilly exclusivity in the United States for the period of the patent term, which runs until the earliest expiry of the earliest priority date plus 20 years. The exclusivity helps secure reimbursement and limits generic entry until the patent lapses or is invalidated. [2]

Are there related patents or potential challenges?
Eli Lilly holds several related CDK4/6 patents, including US 20120184243 A1 (combinations with endocrine therapy) and US 20170321142 A1 (prodrug formulations). No major litigation has been reported against US 2010/0160340 A1, and the claims have survived prior art challenges during examination. Competitors such as Pfizer (Palbociclib) and Roche (Abemaciclib alternative analogues) pursue separate, non‑infringing patents that focus on different chemical scaffolds. [3]

When will the patent expire?
Because the priority date is 2009, the 20‑year term ends in 2029. Patent term adjustments, such as regulatory patent term extensions, could extend this period, but no such extensions have been granted publicly. [2]

How can I look up the patent?
Enter the application number “US 2010/0160340 A1” in Google Patents, the USPTO database, or the WIPO PATENTSCOPE. The public PDF contains full claims, description, and bibliographic information. Search for “abemaciclib” or “CDK4/6 inhibitor” to find related filings. [1]

Sources
[1] Google Patents: US 2010/0160340 A1 – Inhibitors of cyclin‑dependent kinases 4 and 6 – https://patents.google.com/patent/US20100160340A1
[2] Eli Lilly Patents Portfolio – https://www.elililly.com/patents
[3] USPTO Patent Search – https://patft.uspto.gov